All In MedTech

Device Trial Radar · NCT02399124

Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 2014

Primary completion

Feb 2026

Study completion Jul 26, 2026

Sponsor

Lead sponsor
IceCure Medical Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Bnai Zion Medical Center; Assaf-Harofeh Medical Center
First posted
Mar 26, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This experiment is designed for post marketing data collection of a cryosurgical system \[PROSENSE™ of IceCure Medical\], for the treatment of renal cell carcinoma (RCC).

Conditions

  • Renal Cell Carcinoma

Interventions

  • PROSENSE™Device

    single arm, open label, PROSENSE™ treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success in creating an ice ball that engulfs the whole tumor with 5 mm margins using the ProSense™ as seen under laparoscopic, US or CT imaging during the procedure.Time frame: During intervention
  2. Recurrence free survivalTime frame: up to 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Bnei Zion Medical Center

    Haifa, Israel

  • Shamir Medical Center

    Tsrifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.